Vanda Pharmaceuticals | VNDA - Trade Creditors


Vanda Pharmaceuticals reported $39.09M in Trade Creditors for its fiscal quarter ending in December of 2024.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
Akebia Therapeutics USD 9.42M 1.04M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Anika Therapeutics USD 6.24M 103K Jun/2026
Arrowhead Research USD 27.78M 2.97M Jun/2026
AstraZeneca USD 22.89B 388M Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Halozyme Therapeutics USD 23.61M 9.51M Jun/2026
Heron Therapeutics USD 11.64M 2.67M Jun/2026
Insmed USD 74.55M 1.18M Jun/2026
J&J USD 9.22B 1.24B Jun/2026
Lexicon Pharmaceuticals USD 3M 87K Mar/2026
Ligand Pharmaceuticals USD 9.4M 27.7M Jun/2026
Merck USD 3.83B 36M Jun/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Moderna USD 167M 6M Jun/2026
Novartis USD 4.32B 134M Mar/2026
Pfizer USD 4.58B 75M Jun/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 23.6B 888M Jun/2026
Takeda JPY 446.78B 44.56B Jun/2026
Teva Pharmaceutical Industries USD 2.72B 125M Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Veracyte USD 8.02M 1.12M Jun/2026